The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
CAR-T Meeting 2021 | Implementation of CAR T-cell therapy in myeloma: practical and patient-related aspects
Maria-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, outlines the practical and patient-related aspects that need to be considered for the implementation of CAR T-cell therapy in multiple myeloma. In order to select the appropriate therapy for each patient, physicians need to consider different criteria, such as disease morbidity, treatment history, organ function, familiar and social support and quality of life. This interview took place during the 3rd European CAR T-cell Meeting.
